Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)

Tara I. Chang, David M. Reboussin, Glenn M. Chertow, Alfred K. Cheung, William C. Cushman, William J. Kostis, Gianfranco Parati, Dominic Raj, Erik Riessen, Brian Shapiro, George S. Stergiou, Raymond R. Townsend, Konstantinos Tsioufs, Paul K. Whelton, Jeffrey Whittle, Jackson T. Wright, Vasilios Papademetriou

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Studies of visit-to-visit offce blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mmHg) or standard (<140 mmHg) systolic BP targets. We defned OBPV as the coeffcient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no signifcant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95% confdence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confdence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on offce BP control rather than on OBPV unless defnitive benefts of reducing OBPV are shown in prospective trials.

Original languageEnglish (US)
Pages (from-to)751-758
Number of pages8
Issue number4
StatePublished - 2017


  • Angiotensin-converting enzyme inhibitors
  • Blood pressure
  • Heart failure
  • Kidney diseases
  • Mortality

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)'. Together they form a unique fingerprint.

Cite this